Roswell Park Cancer Institute (RPCI) scientists report a novel enzyme inhibitor, Pevonedistat, demonstrated effectiveness in the laboratory against Mantle Cell Lymphoma (MCL), a rare and aggressive subtype of non-Hodgkin Lymphoma.

Twenty-nine physicians from Roswell Park Cancer Institute (RPCI) are included in the Castle Connolly Medical, Ltd. prestigious America’s Top Doctors® list.

The risk of infertility and early menopause increases significantly for women who use tobacco or are exposed to secondhand smoke, according to a study led by Roswell Park researchers and published in the current issue of Tobacco Control.

Physicians now have clearer basis for recommending surgical excision for patients in whom magnetic resonance imaging (MRI) detected lobular neoplasia, a known risk factor for developing breast cancer, according to findings reported in Modern Pathology, by researchers at Roswell Park Cancer Institute (RPCI).

More than a dozen Roswell Park Cancer Institute (RPCI) researchers were invited to present findings at the American Society of Hematology (ASH) 57th Annual Meeting & Exposition, a four-day meeting in Orlando, Fla., that concluded yesterday.

Two studies from JAMA, the Journal of the American Medical Association, report that fewer men are being screened for prostate cancer.

In the five decades since camptothecin was first isolated from the bark of a tree used in traditional Chinese medicine and identified as a powerful anticancer agent, several thousand chemicals with similar structures and functions have been investigated. And while two of these analog compounds, irinotecan and topotecan, have been approved in the U.S. as treatments for cancer, both are associated with significant shortcomings. Researchers from Roswell Park Cancer Institute (RPCI) have reported findings about a new synthetic form of camptothecin, known as FL118, that appears to have greater potency, longer efficacy and fewer adverse side effects than irinotecan and topotecan.